Search

Displaying results 4591 - 4600 of 10000 in total
  1. Drug

    Doramectin

    go.drugbank.com/drugs/DB11400
    ExperimentalVet approved

    in cattle. … Doramectin is a veterinary drug approved by the Food and Drug Administration for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Tecadenoson

    go.drugbank.com/drugs/DB04954
    Investigational

    It is being developed by CV Therapeutics, Inc. … Tecadenoson is a novel selective A1 adenosine receptor agonist that is currently being evaluated for the conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

  3. Drug

    Human Menstrual Blood-derived Stem Cells

    go.drugbank.com/drugs/DB15738
    Investigational

    Because this is a non-invasive way to obtain stem cells, it is simple and easy to obtain the stem cells with an absence of ethical issues that may come from obtaining stem cells of the embryonic kind. … MenSCs are special compared to older methods of adult stem cell extraction such as bone marrow stem cell extraction because MenSC extraction is a non-invasive method.

  4. Drug

    Butyrfentanyl

    go.drugbank.com/drugs/DB09173
    ExperimentalIllicit

    [L7811] This compound is a schedule I controlled substance in the USA because it is a positional isomer of 3-Methylfentanyl. … [A182054] It is an analog of [fentanyl] with roughly 1/30 the potency.[L7811] Butyrfentanyl was first synthesized in 1961 by Janssen Pharmaceuticals as a new opioid analgesic.

  5. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)). … POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD).

  6. Drug

    PBI-1402

    go.drugbank.com/drugs/DB05480
    Experimental

    Since it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 is a small molecule synthetic compound with oral Bioavailability.

  7. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries … Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate
  8. Drug

    SLx-4090

    go.drugbank.com/drugs/DB05678
    Investigational

    SLx-4090 is a microsomal triglyceride transfer protein (MTTP) inhibitor potentially for the treatment of type 2 diabetes. [A33218]

  9. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.

  10. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. … An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity.